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DNA methylation and the epigenetic clock
in relation to physical frailty in older
people: the Lothian Birth Cohort 1936
Catharine R. Gale1,2,3*† , Riccardo E. Marioni2,4†, Sarah E. Harris2,4, John M. Starr2,5 and Ian J. Deary2,3
Abstract
Background: The biological mechanisms underlying frailty in older people are poorly understood. There is some
evidence to suggest that DNA methylation patterns may be altered in frail individuals.
Methods: Participants were 791 people aged 70 years from the Lothian Birth Cohort 1936. DNA methylation was
measured in whole blood. Biological age was estimated using two measures of DNA methylation-based age
acceleration-extrinsic and intrinsic epigenetic age acceleration. We carried out an epigenome-wide association
study of physical frailty, as defined by the Fried phenotype. Multinomial logistic regression was used to calculate
relative risk ratios for being physically frail or pre-frail according to epigenetic age acceleration.
Results: There was a single significant (P = 1.16 × 10–7) association in the epigenome-wide association study
comparing frail versus not frail. The same CpG was not significant when comparing pre-frail versus not frail. Greater
extrinsic epigenetic age acceleration was associated with an increased risk of being physically frail, but not of being
pre-frail. For a year increase in extrinsic epigenetic age acceleration, age- and sex-adjusted relative risk ratios (95%
CI) for being physically frail or pre-frail were 1.06 (1.02, 1.10) and 1.02 (1.00, 1.04), respectively. After further
adjustment for smoking and chronic disease, the association with physical frailty remained significant. Intrinsic
epigenetic age acceleration was not associated with physical frailty status.
Conclusions: People who are biologically older, as indexed by greater extrinsic epigenetic age acceleration, are
more likely to be physically frail. Future research will need to investigate whether epigenetic age acceleration plays
a causal role in the onset of physical frailty.
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Introduction
Frailty is a clinical syndrome that becomes increasingly
common at older ages [1]. Its core features are increased
vulnerability to stressors due to impairments in multiple
systems, decreased physiological reserves, and a decline
in the ability to maintain homeostasis [2]. It increases
the risk of adverse outcomes, including falls, disability,
hospitalization, institutionalization, and death [2–4].
There are two principal models of frailty [2]. Fried’s
phenotype model defines frailty on purely physical
terms, based on three or more components (poor grip
strength, slow walking speed, low physical activity, ex-
haustion, and unintentional weight loss) [3]. The frailty
index, or cumulative deficit model, defines frailty much
more broadly in terms of the accumulation of ‘deficits’
(symptoms, signs, diseases, and disabilities) [5]. The bio-
logical drivers of the multisystem dysregulation that un-
derlies frailty remain unclear, particularly at the cellular
and molecular levels.
Epigenetic changes affect all cells and tissues over the
lifespan [6]. One such change involves alterations to de-
oxyribonucleic acid (DNA) methylation patterns. DNA
methylation is involved in the regulation of gene expres-
sion and occurs at cytosine-phosphate-guanine (CpG)
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sites across the genome [7, 8]. The proportion of methy-
lation at a particular CpG site is referred to as a beta
value, which can change over the life-course [7, 8].
Methylation levels are affected by both genetic and en-
vironmental exposures [9]. The relationship between
DNA methylation levels and aging is complex [10]. Early
evidence showed that global DNA methylation level de-
creases with age, but subsequent studies revealed that
aging is associated with differential methylation (mainly
hypermethylation) of some genomic loci [11]. Multiple
CpG sites have been identified where methylation is as-
sociated with age [12]. Several DNA methylation-based
biomarkers are now used to estimate ‘epigenetic age’
[13, 14] or ‘epigenetic age acceleration,’ a measure of the
difference between predicted epigenetic age and chrono-
logical age’ [15]. These indices—often referred to as the
‘epigenetic clock’—are associated with mortality inde-
pendently of chronological age and other risk factors,
supporting the notion that they capture some aspect of
biological aging [15, 16]. Epigenetic alterations are
thought to be one of the ‘hallmarks’ of aging [10] and
hence may contribute to age-related pathologies such as
frailty. That is, chronological age acts as a proxy for sev-
eral biological changes associated with aging, of which
DNA methylation is one.
Few studies have investigated the relationship between
DNA methylation patterns and frailty in older people.
One study, where frailty status was defined using cluster
analysis, reported that global DNA methylation was
lower in people who were frail compared to the
non-frail, [17], but another study using the Fried pheno-
type of physical frailty found no such association [18].
This latter study also examined associations between
promotor-specific CpG island methylation and frailty
status, and found that lower levels of CpG island methy-
lation were associated with a reduced likelihood of being
frail [18]. Further indications that DNA methylation pat-
terns might differ in people who are frail came in a re-
cent study of 1820 older people which found that
greater epigenetic age acceleration—the difference be-
tween predicted epigenetic age and chronological age—
was associated with greater frailty as measured by a
broadly defined frailty index, such that the frailty index
increased by about 0.25% points per year of epigenetic
age acceleration [19].
Here, we aimed to add to understanding of the rela-
tionship between epigenetic status and physical frailty in
a large, narrow-age sample of 70-year olds. The limited
chronological age range mitigates against cohort expos-
ure effects on DNA methylation thus providing a more
robust context to draw inferences about biological aging
indices. First, we conducted an epigenome-wide associ-
ation study (EWAS) to try to identify whether differen-
tial methylation at specific CpG sites was associated
with current physical frailty status, as defined by the
Fried phenotype. Secondly, we investigated whether
people who were biologically older as indexed by epigen-
etic age acceleration measures were at increased risk of
being physically frail.
Methods
Participants
The Lothian Birth Cohort 1936 (LBC1936) was estab-
lished to study cognitive aging in surviving members of
the 1947 Scottish Mental Survey [20, 21]. 1091
community-dwelling people were recruited aged around
70 years, mostly from the Edinburgh area of Scotland.
This was wave 1 of the LBC1936, data from which are
used in the present study. Ethical approval was obtained
from the Multi-Centre Ethics Committee for Scotland
and Lothian Research Ethics Committee. All subjects
provided written informed consent.
DNA methylation and epigenetic age acceleration measures
Whole blood DNA methylation was measured using the
Illumina HumanMethylation450BeadChips [8] in 1004 par-
ticipants from samples collected at mean age 70 years.
Methodological details about collection of the methylation
data and quality control processes have been reported pre-
viously [9, 22]. Briefly, data were available on 485,512 CpGs
in 920 participants after quality control. This included
background correction, the removal of probes with a low
detection rate, low-quality samples and samples with a low
call rate, and samples where there was a sex or genotype
mismatch. These probes were then used to calculate two
measures of epigenetic age. Calculation of these measures
was done online at https://labs.genetics.ucla.edu/horvath/
dnamage/. First, the epigenetic age of each participant was
estimated from their blood sample in two ways, using the
approaches of Horvarth [13] and Hannum [14]. Intrinsic
epigenetic age acceleration (IEAA) was then defined as the
residuals from a linear regression analysis of Horvarth’s esti-
mate of epigenetic age on chronological age and blood im-
mune cell counts (plasmablasts, naive, and exhausted CD8
+ T cells, CD4+ T cells, natural killer cells, monocytes, and
granulocytes) imputed from methylation data. IEAA is
therefore independent of chronological age and much of
the variation in blood cell composition. IEAA is intended
to capture cell-intrinsic properties of the aging process. Ex-
trinsic epigenetic age acceleration (EEAA) was calculated
by calculating a weighted average of Hannum’s estimate of
epigenetic age and three immune blood cell types known to
change with age, as described in Chen et al. [15], and then
saving the residuals from a linear regression analysis of the
resulting epigenetic age estimate on chronological age.
EEAA tracks both age-related changes in blood cell com-
position and intrinsic epigenetic changes [15]. Like IEAA,
EEAA is independent of chronological age.
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Physical frailty
Physical frailty status was assessed during the LBC1936
wave 1 (mean age 70 years) survey using the Fried frailty
phenotype [3]. Frailty is defined as the presence of three
or more of the following components: weakness,
self-reported exhaustion, slow gait speed, unintentional
weight loss, and low physical activity. Pre-frailty is defined
as the presence of one or two of these components.
Maximum handgrip strength was measured three times
on each side using a dynamometer; the best of these mea-
surements was used for analysis. Body mass index (BMI)
was calculated as weight (in kilograms)/height (in me-
ters)2. Gait speed was assessed by measuring time taken to
walk 6 m at maximum speed. Participants were asked to
indicate their usual level of physical activity on a 6-point
scale, ranging from ‘moving only in connection with ne-
cessary (household) chores’ to ‘keep-fit/heavy exercise or
competitive sport several times a week.’ Symptoms of de-
pression were assessed using the depression subscale of
the Hospital Anxiety and Scale (HADS-D) [23]. We oper-
ationalized the frailty components using definitions simi-
lar to those used in Fried’s original studies [3, 24]:
weakness was defined as maximum grip strength in the
lowest 20% of the distribution, taking account of sex and
BMI; exhaustion was considered present if the participant
responded positively to the HADS-D question ‘I feel as if
I’m slowed down’; slow gait speed was defined as a walk-
ing speed in the lowest 20% of the distribution, taking ac-
count of sex and height; as no information was available
on loss of weight prior to recruitment, we considered par-
ticipants to have unintentional weight loss if they had a
current BMI < 18.5 kg/m2, as has been done previously;
[24] low physical activity was defined as activity in the
lowest sex-specific 20% of the distribution.
Covariates
In addition to age and sex, we used white blood cell
counts as covariates. These are associated with DNA
methylation levels, [25, 26] and were measured in the
same blood sample. Five cell types were assessed: baso-
phils, monocytes, lymphocytes, eosinophils, and neutro-
phils. For measurement details see McIllhagger et al.
[27]. When examining the relationship between epigen-
etic age acceleration measures and physical frailty status,
we also adjusted for smoking status (categorized as
never smoked, ex-smoker, current smoker), units of al-
cohol consumed per week, and number of chronic phys-
ical diseases present. Participants provided information
during interview on whether they had been diagnosed
with diabetes, stroke, cardiovascular disease, high blood
pressure, arthritis, or cancer. We summed the number
of chronic physical conditions present as an indicator of
morbidity burden. This simple measure is a common
way of ascertaining morbidity burden, [28] and has been
shown to be almost as effective at predicting mortality
and health care costs as more complex methods [29].
Statistical analyses
Epigenome-wide association study analyses were con-
ducted whereby each methylation CpG was regressed on
the Fried frailty phenotype (treated as a factor with ‘not
frail’ as the reference category) using linear regression,
adjusting for age, sex, and white blood cell counts. A
Bonferroni p value threshold (0.05/485, 512) was set.
We used multinomial logistic regression to derive rela-
tive risk ratios for being physically frail or pre-frail per
year increase in extrinsic and intrinsic epigenetic age ac-
celeration. Estimates are shown adjusted for age and sex,
then further adjusted for smoking status, alcohol intake,
and number of chronic physical diseases. Sensitivity ana-
lyses were carried out with adjustments for white cell
counts and technical measures related to DNA methyla-
tion typing, namely sample plate, BeadChip, position on
BeadChip, and date.
Analytical sample
Of the 1091 participants who took part in the wave 1
survey, 953 (87.3%) had data on the five components
that are used to derive the Fried phenotype of physical
frailty, and 791 of these (83%) had methylation data after
quality control. The analyses below are based on these
791 participants.
Results
Characteristics of the 791 participants in the study sample
are presented in Table 1 according to frailty status. Their
mean age was 70.0 years (SD 0.84). In total, 7.8% of the
participants were physically frail and 46.0% were pre-frail
as defined by the Fried phenotype. Compared to those
who were not frail, participants who were frail had a
higher mean extrinsic epigenetic age acceleration, higher
mean levels of two types of white cells, monocytes and
neutrophils, more chronic physical illnesses, and a higher
proportion of them were current smokers. Median weekly
alcohol consumption was significantly lower in those who
were frail than in those who were not frail.
The correlation between the two measures of epigen-
etic age acceleration was moderate (r = 0.38, p < 0.0001).
Manhattan plots showing the p values for the CpGs
for physical frailty status (frail versus not frail, and
pre-frail versus not frail) are presented in Fig. 1. There
was a single significant association in the EWAS com-
paring frail versus not frail: cg18314882 on chromosome
8 in the MAF1 gene (p = 1.16 × 10–7): beta 0.0054 (SE
0.0010), indicating hypermethylation. Table 2 reports the
local associations for CpGs within a 1601 base pair re-
gion (the rest of the CpG island). The significant site is
an isolated result. Summary statistics for this CpG were
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mean 0.0118 (SD 0.007), minimum 0.001, maximum
0.105. Figure 2 shows a boxplot of this CpG by frailty
status. A QQ plot of the p values for frail vs not frail is
shown in the Additional file 1: Figure S1. We report the
top 20 CpGs in the Additional file 1: Table S1. None of
them are significant—the smallest p value is 0.012. The
CpG that was significant in the EWAS comparing frail
versus not frail was not significant in the EWAS com-
paring pre-frail versus not frail (p = 0.67).
Table 3 shows relative risk ratios for being physically
frail or pre-frail versus not frail according to the two
measures of epigenetic age acceleration. Greater extrinsic
age acceleration was associated with a slightly increased
risk of being physically frail, but not of being pre-frail, in a
model adjusted for age and sex: for a year increase in
EEAA, the relative risk ratio (RRR) (95% CI) of being
physically frail compared to being not frail was 1.06 (1.02,
1.10). This association was slightly attenuated after further
adjustment for smoking status, alcohol intake, and num-
ber of chronic physical diseases, but remained significant:
RRR (95% CI) was 1.05 (1.01, 1.10). When we adjusted for
presence of cancer, high blood pressure, cardiovascular
Table 1 Characteristics of the study participants according to physical frailty status
Characteristics Total Not frail
(n = 365)
Pre-frail
(n = 364)
Frail
(n = 62)
p value for difference
between not frail and frail
Age (years), mean (SD) 69.5 (0.84) 69.4 (0.88) 69.6 (0.81) 69.5 (0.70) 0.61
Female, number (%) 398 (50.3) 184 (50.4) 181 (49.7) 33 (53.2) 0.17
Epigenetic clock measures (years), mean (SD)
Extrinsic epigenetic age acceleration − 0.39 (7.11) − 1.03 (7.55) − 0.08 (6.73) 1.50 (6.12) 0.013
Intrinsic epigenetic age acceleration − 0.45 (5.99) − 0.78 (6.34) − 0.23 (5.68) 0.20 (5.65) 0.254
Number of chronic physical illnesses, median (IQR) 1 (0–2) 1 (0–1) 1 (0–2) 2 (1–2) 0.0001
Smoking status, number (%)
Never 374 (47.3) 182 (49.9) 168 (46.2) 24 (38.7) 0.005
Ex-smoker 334 (42.2) 154 (42.2) 155 (42.6) 25 (40.3)
Current smoker 83 (10.5) 29 (7.95) 41 (11.3) 13 (21.0)
Units of alcohol per week, median (IQR) 6 (0.5–14) 1 (0–7) 4.25 (0.5–14) 0 (0.25–10) 0.009
White blood cell counts (109/L), median (IQR)
Basophils 0.04 (0.03–0.05) 0.04 (0.03–0.05) 0.04 (0.03–0.05) 0.04 (0.03–0.06) 0.096
Eosinophils 0.13 (0.08–0.21) 0.12 (0.07–0.20 0.12 (0.08–0.22) 0.14 (0.08–0.24) 0.204
Monocytes 0.49 (0.40–0.61) 0.48 (0.38–0.58) 0.52 (0.42–0.63) 0.51 (0.45–0.61) 0.034
Lymphocytes 1.73 (1.40–2.15) 1.68 (1.37–2.05) 1.77 (1.41–2.27) 1.75 (1.48–2.23) 0.105
Neutrophils 4.42 (3.29–5.27) 4.09 (3.23–5.03) 4.29 (3.31–5.36) 4.60 (3.63–5.89) 0.007
Fig. 1 Manhattan plots for frailty versus no frailty and pre-frailty versus no frailty. The solid line represents a Bonferroni significance threshold
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disease, stroke, diabetes, or arthritis as individual disor-
ders, the association was very similar: RRR (95% CI) was
1.06 (1.01, 1.11). Greater intrinsic age acceleration was not
significantly associated with risk of being physically frail
or pre-frail. Relative risk ratios for the abovementioned
analyses were unchanged in sensitivity analyses in which
we additionally adjusted for white cell count and for tech-
nical variables related to the DNA methylation typing.
Discussion
In this cross-sectional survey of 791 men and women
aged 70 years, epigenome-wide association study ana-
lyses found no widespread differences in methylation
patterns between those who were physically frail and
those who were not frail, as defined by the Fried pheno-
type. The proportion of methylation at a single CpG site
(cg18314882 on chromosome 8 in the MAF1 gene) was
significantly different between those two groups. No
such difference at any CpG site was found between
those who were pre-frail and those who were not frail.
These results suggest that blood DNA methylation is
not a good biomarker for physical frailty. Older bio-
logical age as measured by extrinsic epigenetic age accel-
eration was associated with an increased risk of being
physically frail, independent of potential confounding
factors. Intrinsic epigenetic age acceleration was not as-
sociated with increased risk.
To our knowledge, there have been no previous EWAS
of frailty status in later life. Here, we found that the pro-
portion of methylation at one CpG methylation site
(cg18314882 on chromosome 8 in the MAF1 gene) dif-
fered between people who were physically frail and those
who were not frail. There were no similar effect sizes for
other CpGs within in the same region which would have
increased the validity of our finding. Previous evidence
in online databases suggests that this locus is unmethy-
lated in every tissue, such that a beta of 0.02 was found
in the blood, brain, omentum; see for example, Slieker et
al. 2013 where these data are first described [30]. This
limits the implication of this locus given that we found
little indication that methylation was changed in relation
to frailty. MAF1 is a transcriptional repressor. Recent
research has shown that it represses the expression of
both pol III-dependent genes and certain RNA pol
II-dependent genes that play a crucial part in oncoge-
nesis, [31] and is important for the regulation of intra-
cellular lipids [31, 32]. It is likely that MAF1 has a
diversity of physiological functions, but knowledge of its
roles is still limited [33]. It is possible that it could influ-
ence risk of physical frailty via its role in lipid regulation
and hence obesity. Obesity is an established risk factor
for physical frailty [34, 35].
Sarcopenia, an age-related syndrome characterized by
loss of skeletal muscle mass and strength, is a major
contributor to physical frailty [36]. There is evidence
from studies that measured methylation either in muscle
tissue or in whole blood that methylation levels at some
loci may help to explain variations in aging skeletal
muscle mass [37, 38]. In a study comparing DNA
methylation dynamics in skeletal muscle tissue from 24
young male adults and 24 older male adults, 5963 CpG
sites were reported to be differentially methylated be-
tween the two groups; there was predominantly hyper-
methylation throughout the genome in the older group
compared to the young group [37]. In a study of 1550 fe-
male twins that set out to identify genomic regions that
were associated with skeletal muscle mass using methy-
lation levels measured in whole blood, seven associations
between methylation at CpG loci and skeletal muscle
mass were discovered and replicated with a false
Table 2 EWAS output for CpG sites in the same CpG island
(chr8:145158467–145160068:Island) as the top signal (cg18314882)
Probe Beta SE T p
cg02621020 6.15E-04 0.001783 0.345243 7.30E-01
cg08825571 − 1.39E-03 0.000553 − 2.51254 1.22E-02
cg11538573 − 4.82E-04 0.000739 − 0.65216 5.15E-01
cg11883258 3.92E-03 0.004616 0.849065 3.96E-01
cg17170088 6.77E-04 0.000842 0.803668 4.22E-01
cg17176228 2.90E-04 0.000501 0.579033 5.63E-01
cg18314882 5.38E-03 0.001004 5.359905 1.16E-07
cg19517467 − 2.66E-04 0.0016 − 0.16609 8.68E-01
cg20573110 − 7.74E-06 0.001677 − 0.00461 9.96E-01
cg22260950 − 2.28E-04 0.001066 − 0.21425 8.30E-01
cg22861185 9.00E-04 0.000855 1.053655 2.92E-01
cg23119631 − 8.33E-04 0.001081 − 0.77111 4.41E-01
Fig. 2 Boxplot of cg18314882 on chromosome 8 in the MAF1 gene
according to frailty status (0 = not frail, 1 = pre-frail, 2 = frail)
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discovery rate of less than 0.1 [38]. No association be-
tween individual CpG methylation sites and grip
strength was found in a EWAS on the 27 k methylation
array based on a sample of 172 female twins [39].
Our finding that greater extrinsic epigenetic age accel-
eration was associated with an increased risk of being
physically frail is consistent with findings from a
cross-sectional study of 1820 men and women aged 50–
75 years [19]. In that study, greater epigenetic age accel-
eration (defined as the difference between predicted
methylation age and chronological age) was associated
with higher scores on a frailty index made up of 34 po-
tential ‘deficits,’ such that that the frailty index increased
by about 0.25% points per year of epigenetic age acceler-
ation. There tends to be a moderate correlation between
scores on a frailty index and physical frailty status as de-
fined by the Fried phenotype [40], but they differ in that
while the latter describes a specific clinical syndrome
[41], the cumulative deficit model describes the general
state or condition of an individual. The fact that greater
epigenetic age acceleration has been shown to be associ-
ated with greater risk of being physically frail and of
scoring higher on a more broadly defined frailty index
[19] adds to the evidence that people who are frail are
likely to be biologically older.
Intrinsic epigenetic age acceleration was designed to es-
timate “pure” epigenetic aging effects that are not influ-
enced by differences in blood cell counts [15]. In the
current study, it was moderately correlated with extrinsic
epigenetic age acceleration (r = 0.38), and in contrast to
the latter, it was not significantly associated with risk of
being physically frail. Although both these epigenetic age
acceleration measures are predictive of mortality [15],
findings that intrinsic epigenetic age acceleration but not
extrinsic epigenetic age acceleration predicts lung cancer
[42] and is associated with being a centenarian [43] have
led to the suggestion that it may capture a cell-type inde-
pendent component of the aging process [15].
One potential limitation of our study is that of the 1091
individuals who took part in the survey, 791 (73%) could
be included in the current study. Some individuals were
missing data on the physical activity component of the
Fried phenotype of frailty and some had missing methyla-
tion data. Another limitation is that we were only able to
look at methylation markers in blood rather than in any
other tissues in relation to physical frailty. Our EWAS
findings may be due to either a genuine null association
between blood-based methylation markers and physical
frailty or a lack of statistical power in our current analyses.
In this cross-sectional survey of 70-year-old men and
women, we found evidence that those who were bio-
logically older, as indexed by greater extrinsic epigenetic
age acceleration, were more likely to be physically frail.
Future research will need to investigate whether epigen-
etic age acceleration plays a causal role in the onset of
physical frailty.
Additional file
Additional file 1: Table S1. EWAS output for the top 20 CpG sites from
the analysis of frailty vs no frailty. Figure S1. EWAS-QQ plot of the p values
for frail vs not frail. (DOCX 692 kb)
Abbreviations
BMI: Body mass index; CpG: Cytosine-phosphate-guanine;
DNA: Deoxyribonucleic acid; EEAA: Extrinsic epigenetic age acceleration;
EWAS: Epigenome-wide association study; HADS-D: Hospital Depression and
Anxiety Scale Depression subscale; IEAA: Intrinsic epigenetic age acceleration;
IQR: Interquartile range; LBC1936: Lothian Birth Cohort 1936; SD: Standard deviation
Acknowledgements
We thank the Lothian Birth Cohort 1936 members, investigators, research
associates, and team members. We also thank the radiographers at the Brain
Research Imaging Centre and the research nurses and Genetics Core staff at
the Wellcome Trust Clinical Research Facility.
Funding
LBC1936 data collection is supported by the Disconnected Mind project
(funded by Age UK and MRC [Mr/M01311/1 and G1001245/96077]) and
undertaken within the University of Edinburgh Centre for Cognitive Ageing and
Cognitive Epidemiology (funded by the BBSRC and MRC as part of the LLHW
[MR/K026992/1]). Methylation typing was supported by The Wellcome Trust
Institutional Strategic Support Fund and the University of Edinburgh Gertrude
Winifred Gear Fund. The funders played no part in the design of the study,
collection, analysis, and interpretation of data, or in writing the manuscript.
Availability of data and materials
Due to ethical restrictions, data are available upon request from the Lothian
Birth Cohort 1936 Study. To request the data, readers should contact the
principal investigator, Ian Deary, who can be contacted at i.deary@ed.ac.uk.
Table 3 Relative risk ratios (95% confidence intervals) for being physically frail or pre-frail according to epigenetic age acceleration
at age 70
Epigenetic age acceleration measures, per year increase Relative risk ratios (95% CI)
Extrinsic epigenetic age acceleration Not frail Pre-frail Frail
Adjusted for age and sex Reference 1.02 (1.00, 1.04), p = 0.083 1.06 (1.02, 1.10), p = 0.006
Multivariable-adjusted1 Reference 1.02 (0.99, 1.04), p = 0.123 1.05 (1.01, 1.09), p = 0.023
Intrinsic epigenetic age acceleration
Adjusted for age and sex Reference 1.01 (0.99, 1.04), p = 0.248 1.03 (0.98, 1.08), p = 0.225
Multivariable-adjusted1 Reference 1.01 (0.99, 1.04), p = 0.316 1.02 (0.97, 1.06), p = 0.523
1Adjusted for age, sex, smoking status, alcohol intake, and number of chronic physical illnesses
Gale et al. Clinical Epigenetics  (2018) 10:101 Page 6 of 8
Authors’ contributions
IJD is director of the LBC1936 study. REM arranged the measurement of
DNA methylation and epigenetic age acceleration and carried out the
epigenome-wide association study. CRG conducted the analyses of
epigenetic age acceleration in relation to physical frailty and wrote the first
draft of the manuscript. All authors have read and commented on the
manuscript and approved the final version.
Ethics approval and consent to participate
Ethical approval was obtained from the Multi-Centre Ethics Committee for
Scotland and Lothian Research Ethics Committee. All participants gave
written informed consent.
Consent for publication
Not applicable.
Competing interests
IJD is supported by Age UK. The other authors declare that they have no
competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1MRC Lifecourse Epidemiology Unit, Southampton General Hospital,
University of Southampton, Southampton SO16 6YD, UK. 2Centre for
Cognitive Ageing and Cognitive Epidemiology, University of Edinburgh, 7
George Square, Edinburgh EH8 9JZ, UK. 3Department of Psychology,
University of Edinburgh, Edinburgh EH8 9JZ, UK. 4Medical Genetics Section,
Centre for Genomics and Experimental Medicine, Institute of Genetics and
Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK.
5Alzheimer Scotland Dementia Research Centre, University of Edinburgh,
Edinburgh EH8 9JZ, UK.
Received: 7 February 2018 Accepted: 26 July 2018
References
1. Gale CR, Cooper C, Aihie SA. Prevalence of frailty and disability: findings
from the English Longitudinal Study of Ageing. Age Ageing. 2015;44:162–5.
2. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people.
Lancet. 2013;381:752–62. https://doi.org/10.1016/S0140-6736(12)62167-9.
3. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al.
Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med
Sci. 2001;56:M146–M56. http://www.ncbi.nlm.nih.gov/pubmed/11253156
4. Boyd CM, Xue QL, Simpson CF, Guralnik JM, Fried LP. Frailty, hospitalization,
and progression of disability in a cohort of disabled older women. Am J
Med. 2005;118:1225–31. https://doi.org/10.1016/j.amjmed.2005.01.062.
5. Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J
Gerontol A Biol Sci Med Sci. 2007;62:722–7. http://www.ncbi.nlm.nih.gov/
pubmed/17634318
6. Talens RP, Christensen K, Putter H, Willemsen G, Christiansen L, Kremer D, et
al. Epigenetic variation during the adult lifespan: cross-sectional and
longitudinal data on monozygotic twin pairs. Aging Cell. 2012;11:694–703.
https://doi.org/10.1111/j.1474-9726.2012.00835.x.
7. Beck S, Rakyan VK. The methylome: approaches for global DNA methylation
profiling. Trends Genet. 2008;24:231–7. https://doi.org/10.1016/j.tig.2008.01.006.
8. Bibikova M, Barnes B, Tsan C, Ho V, Klotzle B, Le JM, et al. High density DNA
methylation array with single CpG site resolution. Genomics. 2011;98:288–
95. https://doi.org/10.1016/j.ygeno.2011.07.007.
9. Shah S, McRae AF, Marioni RE, Harris SE, Gibson J, Henders AK, et al.
Genetic and environmental exposures constrain epigenetic drift over the
human life course. Genome Res. 2014;24:1725–33. https://doi.org/10.1101/
gr.176933.114.
10. Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks
of aging. Cell. 2013;153:1194–217. https://doi.org/10.1016/j.cell.2013.05.039.
11. Gensous N, Bacalini MG, Pirazzini C, Marasco E, Giuliani C, Ravaioli F, et al.
The epigenetic landscape of age-related diseases: the geroscience
perspective. Biogerontology. 2017;18:549–59. https://doi.org/10.1007/
s10522-017-9695-7.
12. Florath I, Butterbach K, Muller H, Bewerunge-Hudler M, Brenner H. Cross-
sectional and longitudinal changes in DNA methylation with age: an
epigenome-wide analysis revealing over 60 novel age-associated CpG sites.
Hum Mol Genet. 2014;23:1186–201. https://doi.org/10.1093/hmg/ddt531.
13. Horvath S. DNA methylation age of human tissues and cell types. Genome
Biol. 2013;14:R115. https://doi.org/10.1186/gb-2013-14-10-r115.
14. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sadda S, et al. Genome-
wide methylation profiles reveal quantitative views of human aging rates.
Mol Cell. 2013;49:359–67. https://doi.org/10.1016/j.molcel.2012.10.016.
15. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai PC, et al.
DNA methylation-based measures of biological age: meta-analysis
predicting time to death. Aging (Albany NY). 2016;8:1844–65. https://doi.
org/10.18632/aging.101020.
16. Perna L, Zhang Y, Mons U, Holleczek B, Saum KU, Brenner H. Epigenetic age
acceleration predicts cancer, cardiovascular, and all-cause mortality in a
German case cohort. Clin Epigenetics. 2016;8:64. https://doi.org/10.1186/
s13148-016-0228-z.
17. Bellizzi D, D'Aquila P, Giordano M, Montesanto A, Passarino G. Global DNA
methylation levels are modulated by mitochondrial DNA variants.
Epigenomics. 2012;4:17–27. https://doi.org/10.2217/epi.11.109.
18. Collerton J, Gautrey HE, van Otterdijk SD, Davies K, Martin-Ruiz C, von
Zglinicki T, et al. Acquisition of aberrant DNA methylation is associated with
frailty in the very old: findings from the Newcastle 85+ study.
Biogerontology. 2014;15:317–28. https://doi.org/10.1007/s10522-014-9500-9.
19. Breitling LP, Saum KU, Perna L, Schottker B, Holleczek B, Brenner H. Frailty is
associated with the epigenetic clock but not with telomere length in a German
cohort. Clin Epigenetics. 2016;8:21. https://doi.org/10.1186/s13148-016-0186-5.
20. Deary IJ, Gow AJ, Pattie A, Starr JM. Cohort profile: the Lothian birth cohorts
of 1921 and 1936. Int J Epidemiol. 2012;41:1576–84.
21. Deary IJ, Gow AJ, Taylor MD, Corley J, Brett C, Wilson V, et al. The Lothian
Birth Cohort 1936: a study to examine influences on cognitive ageing from
age 11 to age 70 and beyond. BMC Geriatr. 2007;7:28. https://doi.org/10.
1186/1471-2318-7-28.
22. Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, et al. DNA
methylation age of blood predicts all-cause mortality in later life. Genome
Biol. 2015;16:25. https://doi.org/10.1186/s13059-015-0584-6.
23. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale.
Acta Psychiatrica Scandinavica. 1983;67:361–370. <Go to ISI>://
A1983QV25600001.
24. Bandeen-Roche K, Xue QL, Ferrucci L, Walston J, Guralnik JM, Chaves P,
et al. Phenotype of frailty: characterization in the women's health and
aging studies. J Gerontol A Biol Sci Med Sci. 2006;61:262–6.
25. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ,
Nelson HH, et al. DNA methylation arrays as surrogate measures of cell
mixture distribution. BMC Bioinformatics. 2012;13:86. https://doi.org/10.1186/
1471-2105-13-86.
26. Jaffe AE, Irizarry RA. Accounting for cellular heterogeneity is critical in
epigenome-wide association studies. Genome Biol. 2014;15:R31. https://doi.
org/10.1186/gb-2014-15-2-r31.
27. McIlhagger R, Gow AJ, Brett CE, Corley J, Taylor M, Deary IJ, et al.
Differences in the haematological profile of healthy 70 year old men
and women: normal ranges with confirmatory factor analysis. BMC
Blood Disord. 2010;10:4. https://doi.org/10.1186/1471-2326-10-4.
28. Huntley AL, Johnson R, Purdy S, Valderas JM, Salisbury C. Measures of
multimorbidity and morbidity burden for use in primary care and
community settings: a systematic review and guide. Ann Fam Med. 2012;10:
134–41. https://doi.org/10.1370/afm.1363.
29. Perkins AJ, Kroenke K, Unützer J, Katon W, Williams JW, Hope C, et al.
Common comorbidity scales were similar in their ability to predict
health care costs and mortality. J Clin Epidemiol. 2004;57:1040–8.
30. Slieker RC, Bos SD, Goeman JJ, Bovee JV, Talens RP, van der Breggen R,
et al. Identification and systematic annotation of tissue-specific
differentially methylated regions using the Illumina 450k array.
Epigenetics Chromatin. 2013;6:26. https://doi.org/10.1186/1756-8935-6-26.
31. Moir RD, Willis IM. Regulating maf1 expression and its expanding biological
functions. PLoS Genet. 2015;11:e1004896. https://doi.org/10.1371/journal.
pgen.1004896.
32. Palian BM, Rohira AD, Johnson SA, He L, Zheng N, Dubeau L, et al.
Maf1 is a novel target of PTEN and PI3K signaling that negatively
regulates oncogenesis and lipid metabolism. PLoS Genet. 2014;10:
e1004789. https://doi.org/10.1371/journal.pgen.1004789.
Gale et al. Clinical Epigenetics  (2018) 10:101 Page 7 of 8
33. Khanna A, Pradhan A, Curran SP. Emerging roles for Maf1 beyond the
regulation of RNA polymerase III activity. J Mol Biol. 2015;427:2577–85.
https://doi.org/10.1016/j.jmb.2015.06.022.
34. Hubbard RE, Lang IA, Llewellyn DJ, Rockwood K. Frailty, body mass
index, and abdominal obesity in older people. J Gerontol A Biol Sci
Med Sci. 2010;65:377–81. https://doi.org/10.1093/gerona/glp186.
35. Porter Starr KN, McDonald SR, Bales CW. Obesity and physical frailty in
older adults: a scoping review of lifestyle intervention trials. J Am Med
Dir Assoc. 2014;15:240–50. https://doi.org/10.1016/j.jamda.2013.11.008.
36. Reginster JY, Cooper C, Rizzoli R, Kanis JA, Appelboom G, Bautmans I,
et al. Recommendations for the conduct of clinical trials for drugs to
treat or prevent sarcopenia. Aging Clin Exp Res. 2016;28:47–58. https://
doi.org/10.1007/s40520-015-0517-y.
37. Zykovich A, Hubbard A, Flynn JM, Tarnopolsky M, Fraga MF, Kerksick C,
et al. Genome-wide DNA methylation changes with age in disease-free
human skeletal muscle. Aging Cell. 2014;13:360–6. https://doi.org/10.
1111/acel.12180.
38. Livshits G, Gao F, Malkin I, Needhamsen M, Xia Y, Yuan W, et al.
Contribution of heritability and epigenetic factors to skeletal muscle
mass variation in United Kingdom twins. J Clin Endocrinol Metab. 2016;
101:2450–9. https://doi.org/10.1210/jc.2016-1219.
39. Bell JT, Tsai PC, Yang TP, Pidsley R, Nisbet J, Glass D, et al. Epigenome-
wide scans identify differentially methylated regions for age and age-
related phenotypes in a healthy ageing population. PLoS Genet. 2012;8:
e1002629. https://doi.org/10.1371/journal.pgen.1002629.
40. Gale CR, Cooper C. Attitudes to ageing and change in frailty status: the
English longitudinal study of ageing. Gerontology. 2017; https://doi.org/
10.1159/000477169.
41. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, et al.
Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–7.
https://doi.org/10.1016/j.jamda.2013.03.022.
42. Levine ME, Hosgood HD, Chen B, Absher D, Assimes T, Horvath S. DNA
methylation age of blood predicts future onset of lung cancer in the
women’s health initiative. Aging (Albany NY). 2015;7:690–700. https://
doi.org/10.18632/aging.100809.
43. Horvath S, Pirazzini C, Bacalini MG, Gentilini D, Di Blasio AM, Delledonne M,
et al. Decreased epigenetic age of PBMCs from Italian semi-
supercentenarians and their offspring. Aging (Albany NY). 2015;7:1159–70.
https://doi.org/10.18632/aging.100861.
Gale et al. Clinical Epigenetics  (2018) 10:101 Page 8 of 8
